Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RCUS
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
RCUS
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

RCUS Similar Chart Price Prediction

The price of RCUS is predicted to go up -9.68%, based on the high correlation periods with CANF. The similarity of these two price pattern on the periods is 97.49%.

stocks logo

RCUS

stocks logo

CANF

Down: -9.68%Similarity: 97.49%

RCUS Revenue Forecast

RCUS EPS Forecast

RCUS FAQs

What is bull’s view on RCUS?

RCUS stock closed at $12.90 on January 31, 2025, down 3.59% during regular trading. Despite being near its 52-week low of $12.88, its RSI of 29.9 indicates oversold conditions, suggesting potential for a rebound. Bulls may target $16.43, the last trade above its 200-day moving average, as a recovery level.

What is bear's view on RCUS?

RCUS stock is currently bearish, trading at $12.90, near its 52-week low of $12.88. The RSI of 29.9 indicates oversold conditions, but the stock has faced heavy selling pressure, dropping 3.59% on January 31. Without a clear catalyst for recovery, the bearish trend may persist in the short term.

What is RCUS revenue forecast for next quarter？

The market consensus for RCUS's revenue in the upcoming quarter is projected to be approximately $40.7M USD.

What is RCUS eps forecast for next quarter？

The market consensus for RCUS's eps in the upcoming quarter is projected to be approximately $1.06 USD.

RCUS VS S&P500

Ask Intellectia about RCUS

RCUS Analyst's Forecast

Peter Lawson

Barclays

Buy

Price Target

$25 → $29

Upside

+77.7%

Barclays analyst Peter Lawson raised the firm's price target on Arcus Biosciences to $29 from $25 and keeps an Overweight rating on the shares. While the HIF2alpha data confirmed overall response rate is in line with Merck, there are multiple paths to higher rate with five patients still on study, the analyst tells investors in a research note.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free